Navigation Links
Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
Date:5/6/2013

nfectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development and Janssen Biotech are part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
9. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
10. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
11. CombiMatrix Corporation Selects Cartagenia BENCHlab CNV Platform to Bolster Expanded Lab Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
(Date:12/19/2014)... (HealthDay News) -- Injectable drug users who also use ... rate of other substance users, a new study finds. ... the risk of suicide attempt and completed suicide," Didier ... said in a university news release. "However, there are ... know who among substance users were actually more likely ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The cost of cancer ... a new study finds. Researchers examined data from ... diagnosed with colorectal or lung cancer. Of those patients, ... and more than 100 had advanced cancer. Nearly ... pay their medical bills, which was linked with a ...
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... the United States -- along with Angelina Jolie,s chickenpox ... highlighted cracks in the nation,s public health defense against ... released Thursday. Half of U.S. states are poorly ... outbreaks. That was the main conclusion of the report ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Hospital in Franklin, Ind. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... service hospital providing care to the residents of Johnson ...
Breaking Medicine News(10 mins):Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... Phase II Clinical Trial conducted by a cancer institute in ... kidney cancer with the help of bevacizumab and erlotinib[1], the ... and may help in prolonging patient's survival. ,Renal ... especially once it has started to spread to other sites ...
... vision through cell transplants when they treated animals suffering from ... eye damages similar to that seen in many human eye ... which had lost their sight, leading to hopes that it ... happened when immature retinal stem cells were transplanted into the ...
... The AMA Federal Council has rejected outright Pharmaceutical ... are currently being pushed by some medical groups. ... today that any PBS savings derived from changed ... PBS. ,'Evidence-based prescribing information and other ...
... (ADRA) is making preparations for the annual commemoration of World ... is meant to be observed as the international day of ... ,The theme of ADRA's for 2006 is, "AIDS ... and it encourages people all over the world to realize ...
... of developing pancreatic cancer increases by 90% with the intake of ... 70% higher in people who added sugar to any food or ... who added no sugar. ,In spite of high sugar ... the first time that researchers have shown a direct association between ...
... breast cancer charity went bankrupt after it was apparent ... the cause. // Tony Freeman, 40, the man who ... at the High Court in Glasgow for 18 months ... Consultancy (Solutions RMC), raised money for several cancer charities, ...
Cached Medicine News:Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Cell Transplants Can Even Help In Restoring Vision 2Health News:Commemoration of World AIDS Day 2Health News:Charity swindler jailed over cash fraud 2
... analyzer is an affordable system offering ... reliability and consistency of state-of-the-art instrument-based ... way to obtain dependable urine chemistry ... economy of motion and superior efficiency ...
... device consists of a non-compliant balloon with ... longitudinally on its outer surface. When the ... atherotomes score the plaque, creating initiation sites ... as Atherotomy, allows dilatation of the target ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
Medicine Products: